Search Results
256 Results for 'Therapeutics & Vaccines'
PAGE 1 OF 11
Technology
MINERAL-COATED IRON OXIDE MICROPARTICLES AND USE OF SAME FOR IMMUNOMODULATION
Building off earlier work relating to mineral coatings, UW-Madison researchers have extended this work to FeOs to generate mineral-coated FeO microparticles (FeO MCMs). The FeO MCMs are created using ...
Learn More
Learn More
William Murphy, Hannah Brinkman, Iris Baurceanu | P230080US02
Technology
COMBINATION TUMOR THERAPY WITH THROMBOSIS INITIATION AND PLATELET RECRUITMENT
UW-Madison researchers have created a “cellular hive” that addresses the shortcomings of existing ICB-based immunotherapy. In short, the inventors leverage a two-part system that mimics the coagul...
Learn More
Learn More
Quanyin Hu, Yixin Wang | P230031US02
Technology
COLD-ADAPTED, LIVE ATTENUATED SARS-COV-2 VACCINE
The present invention relates to cold-adapted SARS-CoV-2 viruses created and being characterized by Dr. Kawaoka’s team at U. Tokyo. The researchers have passaged the isolate (SARS-CoV-2/UW-001/Human...
Learn More
Learn More
Yoshihiro Kawaoka, Seiya Yamayoshi, Satoshi Kamakura | P210139US04
Technology
SYSTEM FOR DETECTING AMYLOID BETA OLIGOMER BINDERS
UW-Madison researchers have developed a new way to select protein and cyclic peptide binders of amyloid-β (Aβ) oligomers. This innovation uses a transcription factor that the inventors previously en...
Learn More
Learn More
Tina Wang, Byung Uk Lee | P240145US02
Technology
HYDROGEL COMPOSITIONS FOR USE FOR DEPLETION OF TUMOR ASSOCIATED MACROPHAGES
UW-Madison researchers have developed a biocompatible alginate-based hydrogel containing Pexidartinib (PLX) loaded nanoparticles (PLX-NPs) alone or in combination with platelet conjugated aPD-1 (P-aPD...
Learn More
Learn More
Quanyin Hu, Yingyue Ding, Zhaoting Li | P210433US02
Technology
Treatment of Solid Tumors With a Regimen of Targeted Radionuclide Therapy and Genetically Engineered Immune Cell Therapies
UW-Madison researchers have developed a combination of low dose radiation with a CAR T cell to treat solid tumors. They provided a low dose of targeted radionuclide therapy given prior to CAR T cell i...
Learn More
Learn More
Zachary Morris, Quaovi Sodji, Christian Capitini | P240021US02
Technology
Models and Methods for Predicting Cell-Surface Protein Expression
A UW-Madison researcher has developed a web-based atlas of cell surface target (CST) protein expression across various cancer types. This system can be used to identify understudied drug targets for t...
Learn More
Learn More
Shuang Zhao | P240384US02
Technology
GENERATION OF INDUCED NEUTROPHILS WITH INCREASED ACTIVATION AND TRANSMIGRATION CAPABILITIES
UW-Madison researchers have discovered that MYDGF-knockout iNeutrophils (neutrophils produced through differentiation from pluripotent stem cells) have the ability to efficiently migrate across endoth...
Learn More
Learn More
Anna Huttenlocher, David Bennin, Frances Smith | P240375US02
Technology
Antifungal Diferulic Acid Formulation Containing Poacic Acid and Poacidiene, Method for Production, and Method of Using Same
UW-Madison researchers have developed a method of using a combination of derivatives of lignin molecules to treat fungal pathogens. The researchers have studied a combination of two molecules that are...
Learn More
Learn More
John Ralph, Fachuang Lu, Mehdi Kabbage | P240103US02
Technology
Fusion Cytokine Compositions and Methods of Use Thereof
UW-Madison researchers have developed a glioblastoma cancer vaccine using primary tumor cells transfected with a genetic construct expressing a fusion of IL-7 and GM-CSF. The transfected cells are tre...
Learn More
Learn More
Jacques Galipeau, Mahua Dey | P230246US02
Technology
COMPOSITIONS AND METHODS FOR BACTERIOPHAGE INFECTION OF STAPHYLOCOCCUS BACTERIA
UW-Madison researchers are developing a phage therapy method for treating drug resistant bacteria such as MRSA and Staphylococcus epidermidis. The inventors recently discovered that infection by a sta...
Learn More
Learn More
Charlie Mo, My Tran, Angel Hernandez Viera | P240267US02
Technology
DEGRADATION TARGETING AGENTS AND USES THEREOF
UW-Madison researchers have discovered two peptides, HLTF;zf-C3HC4 and RO52;zf-C3HC4 (hereafter referred to as the HLTF peptide and the RO52 peptide) which, when tethered to a protein induce degradati...
Learn More
Learn More
Gaelen Hess, Grace Boyum | P250015US03
Technology
Compositions and Methods for Reducing the Rate of Type 1 Diabetes
A UW researcher has developed a method of supplementing the diet of infants to prevent the development of type 1 diabetes in children. This researcher also developed a synthetic insulin analog that pr...
Learn More
Learn More
Michael MacDonald | P230019US02
Technology
Cyclic Peptide-Based Lysosome Targeting Degraders
UW-Madison researchers have developed a protein degrader that shuttles targeted extracellular protein into the lysosome using a cyclic peptide that binds to a cellular receptor attached to a binding m...
Learn More
Learn More
Weiping Tang, Yaxian Zhou, Yuan Zhao | P220339US02
Technology
DESIGN AND APPLICATION OF NOVEL PHOTORECEPTOR-SPECIFIC PROMOTERS FOR RETINAL GENE THERAPY APPLICATIONS
UW-Madison researchers have developed a novel photoreceptor specific promoter-enhancer construct that they call “IMPG2 PE1”, which is based on two distinct regulatory sequences of the human Interp...
Learn More
Learn More
David Gamm, Yashdeep Phanse | P240064US02
Technology
L. Reuteri Engineered to Release Recombinant Products Following Prophage Activation and Subsequent Phage-Mediated Lysis
A UW-Madison researcher has engineered Lactobacillus reuteri (L. reuteri VPL1014) to express a recombinant gene from the chromosome or plasmid. The gene product can be rodent-, monkey-, or human-deriv...
Learn More
Learn More
Jan Peter Van Pijkeren | P250218US01
Technology
MOUSE MODEL: PPCD1-Delta 40 ("CURE FOR POSTERIOR POLYMORPHOUS CORNEAL DYSTROPHY (PPCD)")
UW-Madison researchers have developed a mouse model (PPCD1-Delta 40) for Posterior Polymorphous Corneal Dystrophy (PPCD).They have also developed second mouse model (see P250382US01 below).
Learn More
Learn More
Christopher Bradfield, Anna Lee Shen, Alex Veith | P250382US02
Technology
MOUSE MODEL: PPCD1 ("CURE FOR POSTERIOR POLYMORPHOUS CORNEAL DYSTROPHY (PPCD)")
UW-Madison researchers have developed a mouse model (PPCD1) for Posterior Polymorphous Corneal Dystrophy (PPCD). They have also developed second mouse model (see P250382US02 below).
Learn More
Learn More
Christopher Bradfield, Anna Lee Shen, Alex Veith | P250382US01
Technology
L. Reuteri Engineered to Release Recombinant Products Following Antirepressor Induction Leading to Prophage Activation and Subsequent Phage-Mediated Lysis
A UW-Madison researcher has engineered Lactobacillus reuteri (L. Reuteri VPL1014) to encode a native antirepressor protein whose expression is placed under the control of an inducible promoter along w...
Learn More
Learn More
Jan Peter Van Pijkeren | P250219US01
Technology
Novel Cancer Immunotherapeutics Using Artificial Intelligence
UW-Madison researchers have developed an AI-based method for designing humanized CAR sequences. Using this method, they developed two novel humanized CD19 sequences that can be used for production of ...
Learn More
Learn More
Krishanu Saha, Srikumar Sengupta | P250280US01
Technology
Methods of Treating Epilepsy and Reducing the Incidence of Seizures
UW-Madison researchers have developed a method for stopping seizures in patients suffering from acquired epilepsy. The treatment strategy utilizes Tofacitinib, a JAK/STAT inhibitor currently prescribe...
Learn More
Learn More
Avtar Roopra, Olivia Hoffman | P240298US02
Technology
A UW-Madison researcher has developed an oral combination therapy for treating fibrolamellar carcinoma (FLC) that utilizes a CDK7 inhibitor and a CDK9 inhibitor. The researcher created a cancer cell l...
Learn More
Learn More
Sean Ronnekleiv-Kelly | P240225US02
Technology
Antimony Chelates For Targeted Auger Therapy And Imaging Diagnostics
UW-Madison researchers in collaboration with researchers at the Oak Ridge National Laboratory have developed chelated antimony (Sb) that can be used for targeted Auger radiotherapy. While 119Sb has be...
Learn More
Learn More
Jonathan Engle, Aeli Olson, Nikki Thiele, Briana Schrage, Md Faizul Islam | P230454US02
Technology
IFNy AND TFNa CO-STIMULATION OF MESENCHYMAL STROMAL CELLS DERIVED FROM MINOR SALIVARY (LABIAL) GLANDS FOR THERAPEUTIC USE
UW-Madison researchers have developed improved methods for optimizing the characteristics of salivary gland-derived mesenchymal stromal cells (MSCs) for therapeutic administration.The inventors have d...
Learn More
Learn More
Sara McCoy, Jacques Galipeau | P240070US02
Technology
Single-Domain Antibodies and Variants Thereof Against Opioids
UW-Madison researchers and collaborators have developed a suite of four camelid antibodies that specifically bind to fentanyl and carfentanil, a major metabolite of fentanyl. One binds specifically to...
Learn More
Learn More
Aaron LeBeau, Joseph Gallant, Marco Pravetoni, Carly Baehr, Hideki Aihara, Dustin Hicks | P230209US02